This Dyspepsia- Pipeline Insight, 2022 report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Dyspepsia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Dyspepsia is upper abdominal pain or discomfort that is episodic or persistent and often associated with belching, bloating, heartburn and nausea or vomiting. Dyspepsia can be divided into 2 main categories: organic and functional dyspepsia (FD). Organic causes of dyspepsia are peptic ulcer, gastroesophageal reflux disease, gastric or esophageal cancer, pancreatic or biliary disorders, intolerance to food or drugs, and other infectious or systemic diseases. Pathophysiological mechanisms underlying FD are delayed gastric emptying, impaired gastric accommodation to a meal, hypersensitivity to gastric distension, altered duodenal sensitivity to lipids or acids, altered antroduodenojenunal motility and gastric electrical rhythm, unsuppressed postprandial phasic contractility in the proximal stomach, and autonomic nervous system-central nervous system dysregulation. The condition is reported to occur in approximately 25 percent (range: 13 to 40 percent) of the population each year, but most affected persons do not seek medical care. Even though dyspepsia is a highly prevalent condition, no definitive studies have as yet established guidelines for the work-up of dyspeptic patients in the primary care setting. Dyspepsia, often defined as chronic or recurrent discomfort centered in the upper abdomen, can be caused by a variety of conditions. Common etiologies include peptic ulcers and gastroesophageal reflux. Serious causes, such as gastric and pancreatic cancers, are rare but must also be considered. Symptoms of possible causes often overlap, which can make initial diagnosis difficult. In many patients, a definite cause is never established. The initial evaluation of patients with dyspepsia includes a thorough history and physical examination, with special attention given to elements that suggest the presence of serious disease. Endoscopy should be performed promptly in patients who have “alarm symptoms” such as melena or anorexia. Optimal management remains controversial in young patients who do not have alarm symptoms. Because the differential diagnosis of dyspepsia is broad, initial efforts should be focused on the most common etiologies. In about 50 to 60 percent of patients, a specific etiology is not identified (i.e., “functional” or nonulcer dyspepsia). All patients with dyspepsia should be advised to stop smoking and, if their medical condition permits, to discontinue ulcerogenic medications. They should also avoid foods and other factors that precipitate their symptoms. Because dyspepsia may be aggravated by stress, anxiety or depression, it may be useful to explore these issues. Reassurance is a key step in managing dyspepsia, but advice regarding stress-reducing activities such as exercise and relaxation is also important.
“Dyspepsia- Pipeline Insight, 2022 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dyspepsia pipeline landscape is provided which includes the disease overview and Dyspepsia treatment guidelines. The assessment part of the report embraces, in depth Dyspepsia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dyspepsia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Dyspepsia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
RQ-00000010: RaQualia Pharma
RQ-00000010 is a highly-selective serotonin receptor subtype 5HT4 partial-agonist that promotes the motility of the gastrointestinal (GI) tract. RQ-00000010 has the potential to be a significant new therapeutic option for the treatment of Functional Dyspepsia (FD) and other diseases related to GI motility disorders, including Chronic Constipation. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Functional Dyspepsia (FD).
RQ-00201894 : RaQualia Pharma
RQ-00201894, motilin and erythromycin act as full motilin receptor agonists (EC50: 0.20, 0.11, 69 nM, respectively). RQ-00201894 potently and selectively activates the motilin receptor and causes long-lasting facilitation of cholinergic activity in human stomach, an activity thought to correlate with an ability to increase gastric emptying. Currently, the drug is in Pre-Clinical stage of Clinical trial evaluation for the treatment of Functional Dyspepsia.
PCS12852: Processa Pharmaceuticals
PCS12852 is a novel, potent, and highly selective 5-HT4 receptor agonist for treating Gastrointestinal (GI) motility disorder, also called gastrointestinal dysfunction (POGD). These GI disorders take many forms, including chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia, and gastroparesis.
This segment of the report provides insights about the different Dyspepsia drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the therapies for Dyspepsia. The companies which have their Dyspepsia drug candidates in the most advanced stage, i.e. phase II include, Processa Pharmaceuticals.
Phases
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dyspepsia therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dyspepsia drugs.
Geography Covered
- Global coverage
Dyspepsia: Understanding
Dyspepsia: Overview
Dyspepsia is upper abdominal pain or discomfort that is episodic or persistent and often associated with belching, bloating, heartburn and nausea or vomiting. Dyspepsia can be divided into 2 main categories: organic and functional dyspepsia (FD). Organic causes of dyspepsia are peptic ulcer, gastroesophageal reflux disease, gastric or esophageal cancer, pancreatic or biliary disorders, intolerance to food or drugs, and other infectious or systemic diseases. Pathophysiological mechanisms underlying FD are delayed gastric emptying, impaired gastric accommodation to a meal, hypersensitivity to gastric distension, altered duodenal sensitivity to lipids or acids, altered antroduodenojenunal motility and gastric electrical rhythm, unsuppressed postprandial phasic contractility in the proximal stomach, and autonomic nervous system-central nervous system dysregulation. The condition is reported to occur in approximately 25 percent (range: 13 to 40 percent) of the population each year, but most affected persons do not seek medical care. Even though dyspepsia is a highly prevalent condition, no definitive studies have as yet established guidelines for the work-up of dyspeptic patients in the primary care setting. Dyspepsia, often defined as chronic or recurrent discomfort centered in the upper abdomen, can be caused by a variety of conditions. Common etiologies include peptic ulcers and gastroesophageal reflux. Serious causes, such as gastric and pancreatic cancers, are rare but must also be considered. Symptoms of possible causes often overlap, which can make initial diagnosis difficult. In many patients, a definite cause is never established. The initial evaluation of patients with dyspepsia includes a thorough history and physical examination, with special attention given to elements that suggest the presence of serious disease. Endoscopy should be performed promptly in patients who have “alarm symptoms” such as melena or anorexia. Optimal management remains controversial in young patients who do not have alarm symptoms. Because the differential diagnosis of dyspepsia is broad, initial efforts should be focused on the most common etiologies. In about 50 to 60 percent of patients, a specific etiology is not identified (i.e., “functional” or nonulcer dyspepsia). All patients with dyspepsia should be advised to stop smoking and, if their medical condition permits, to discontinue ulcerogenic medications. They should also avoid foods and other factors that precipitate their symptoms. Because dyspepsia may be aggravated by stress, anxiety or depression, it may be useful to explore these issues. Reassurance is a key step in managing dyspepsia, but advice regarding stress-reducing activities such as exercise and relaxation is also important.
“Dyspepsia- Pipeline Insight, 2022 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dyspepsia pipeline landscape is provided which includes the disease overview and Dyspepsia treatment guidelines. The assessment part of the report embraces, in depth Dyspepsia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dyspepsia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Dyspepsia R&D. The therapies under development are focused on novel approaches to treat/improve Dyspepsia.
Dyspepsia Emerging Drugs Chapters
This segment of the Dyspepsia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dyspepsia Emerging Drugs
RQ-00000010: RaQualia Pharma
RQ-00000010 is a highly-selective serotonin receptor subtype 5HT4 partial-agonist that promotes the motility of the gastrointestinal (GI) tract. RQ-00000010 has the potential to be a significant new therapeutic option for the treatment of Functional Dyspepsia (FD) and other diseases related to GI motility disorders, including Chronic Constipation. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Functional Dyspepsia (FD).
RQ-00201894 : RaQualia Pharma
RQ-00201894, motilin and erythromycin act as full motilin receptor agonists (EC50: 0.20, 0.11, 69 nM, respectively). RQ-00201894 potently and selectively activates the motilin receptor and causes long-lasting facilitation of cholinergic activity in human stomach, an activity thought to correlate with an ability to increase gastric emptying. Currently, the drug is in Pre-Clinical stage of Clinical trial evaluation for the treatment of Functional Dyspepsia.
PCS12852: Processa Pharmaceuticals
PCS12852 is a novel, potent, and highly selective 5-HT4 receptor agonist for treating Gastrointestinal (GI) motility disorder, also called gastrointestinal dysfunction (POGD). These GI disorders take many forms, including chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia, and gastroparesis.
Dyspepsia: Therapeutic Assessment
This segment of the report provides insights about the different Dyspepsia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Dyspepsia
There are approx. 5+ key companies which are developing the therapies for Dyspepsia. The companies which have their Dyspepsia drug candidates in the most advanced stage, i.e. phase II include, Processa Pharmaceuticals.
Phases
This report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Dyspepsia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Dyspepsia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dyspepsia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dyspepsia drugs.
Dyspepsia Report Insights
- Dyspepsia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Dyspepsia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Dyspepsia drugs?
- How many Dyspepsia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dyspepsia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dyspepsia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dyspepsia and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- RaQualia Pharma
- Processa Pharmaceuticals
Key Players
- RQ-00000010
- RQ-00201894
- PCS12852
Table of Contents
IntroductionExecutive SummaryDyspepsia- Analytical PerspectiveDyspepsia Key CompaniesDyspepsia Key ProductsDyspepsia - Unmet NeedsDyspepsia - Market Drivers and BarriersDyspepsia - Future Perspectives and ConclusionDyspepsia Analyst ViewsDyspepsia Key CompaniesAppendix
Dyspepsia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Pre - Registration)
Drug Name : Company Name
Last Stage Products (Phase III)
Drug Name : Company Name
Mid Stage Products (Phase II)
PCS12852: Processa Pharmaceuticals
Preclinical and Discovery Stage Products
RQ - 00201894 : RaQualia Pharma
Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- RaQualia Pharma
- Processa Pharmaceuticals
